



GUIDELINES FOR BIOSAMPLE ACCESS

All biosamples within the CanPath Biorepository represent a finite resource. It is the goal of CanPath to use these samples to the best of their potential and CanPath has developed guidelines and review processes to help achieve this goal and support CanPath's mission, vision and values.

Guideline for the release of biosamples include:

| required for an assay will be released. CanPath reserves the right to suggest alternative assays if it uses a smaller biosample volume. |
|--|
| Multiplex assays approaches that minimize volume requirements are preferred. |
| Analytes that have not been measured previously in the same biosample set. |
| Proposed analyte analysis presents a high probability of providing accurate results. |
| Proposed methodology presents a high probability of providing accurate results. |
| Approved biosamples may be conditionally released in a staggered format. Subsequent biosample release is dependent upon successful analysis of the released biosamples including demonstration of assay reproducibility. |
| Additional review will be required when biosamples are at risk of shortage or access to legacy biosamples is required. |
| All biosample requests of >500 μ L for non DNA samples or >2 μ g DNA will require extraordinary scientific justification to be considered. |
| Should multiple requests be reviewed at the same time with overlapping biosamples, then CanPath may suggest combining the analysis into a multiplex assay pending feasibility. |

Approved June 19, 2019 Updated June 26, 2020